Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

631
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
631
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

753
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

597
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
597
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

804
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
804
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

790
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

1.6K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond QRS Duration in Cardiac Resynchronization Therapy.

JACC. Clinical electrophysiology·2026
Same author

Left Bundle Branch Area Pacing Reverts Electromechanical Window Negativity to a Similar Extent as Biventricular Pacing.

Pacing and clinical electrophysiology : PACE·2026
Same author

Ventricular activation and repolarization in response to physiological and conventional pacing using ultra-high-frequency electrocardiography.

PloS one·2026
Same author

Coronary artery disease diagnosis with signal processing and machine learning of heart sound signals: a systematic review.

NPJ digital medicine·2026
Same author

Left bundle branch vs biventricular pacing: mechanistic insights from a canine model.

European heart journal·2026
Same author

Spectral analysis of bruits with an electronic stethoscope enhances screening of carotid stenosis and plaques beyond conventional auscultation.

Annals of translational medicine·2025

Related Experiment Video

Updated: Apr 29, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.2K

Strategies to improve cardiac resynchronization therapy.

Kevin Vernooy1, Caroline J M van Deursen2, Marc Strik1

  • 1Department of Cardiology, Maastricht University Medical Center, PO Box 5800, 6202 AZ Maastricht, Netherlands.

Nature Reviews. Cardiology
|May 21, 2014
PubMed
Summary

Cardiac resynchronization therapy (CRT) improves heart failure outcomes. Optimal patient selection, electrode placement, and stimulation timing are key for maximizing benefits from this pacemaker therapy.

More Related Videos

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

2.4K
Simultaneous Electrical and Mechanical Stimulation to Enhance Cells' Cardiomyogenic Potential
07:41

Simultaneous Electrical and Mechanical Stimulation to Enhance Cells' Cardiomyogenic Potential

Published on: January 18, 2019

7.2K

Related Experiment Videos

Last Updated: Apr 29, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.2K
Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

2.4K
Simultaneous Electrical and Mechanical Stimulation to Enhance Cells' Cardiomyogenic Potential
07:41

Simultaneous Electrical and Mechanical Stimulation to Enhance Cells' Cardiomyogenic Potential

Published on: January 18, 2019

7.2K

Area of Science:

  • Cardiology
  • Biomedical Engineering

Background:

  • Cardiac resynchronization therapy (CRT) is a device therapy for heart failure with abnormal ventricular conduction (wide QRS complex).
  • CRT has been available for two decades.
  • The review focuses on optimizing CRT benefits.

Purpose of the Study:

  • To provide insights into maximizing benefits from cardiac resynchronization therapy.
  • To discuss patient selection, electrode positioning, and stimulation timing for improved CRT outcomes.

Main Methods:

  • Review of existing literature and clinical insights on CRT.
  • Analysis of factors influencing CRT efficacy, including patient characteristics and procedural techniques.

Main Results:

  • Left bundle branch block (LBBB) is the primary indicator for CRT benefit.
  • Patient selection, precise electrode placement (avoiding scar tissue), and optimal stimulation timing significantly impact outcomes.
  • No universal optimal left ventricular pacing site exists; a late-activated site is preferred.

Conclusions:

  • CRT offers significant benefits for select heart failure patients.
  • Improving CRT outcomes requires careful patient selection, procedural optimization, and potentially new electrocardiographic measures for long-term success.